Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naproxen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 11/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 11/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CDC42 | P60953 | 1/20 | 1.00 |
| ▸ | RAC1 | P63000 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naproxen SCHEMBL29360045 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL215236 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL28834409 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL616149 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL42434 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29359528 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350704 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL3046 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL10029028 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL30346195 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117534557-B | Preparation method of D, L-naproxen | 江苏八巨药业有限公司 | 2025-01-24 | — | — | CN | claimed |
| WO-2024075139-A1 | A PROCESS FOR PREPARATION OF FINERENONE AND INTERMEDIATES THEREOF | MAITHRI DRUGS PRIVATE LIMITED (IN) | 2024-04-11 | — | — | WO | claimed |
| CN-117534557-A | Preparation method of D, L-naproxen | 江苏八巨药业有限公司 | 2024-02-09 | — | — | CN | claimed |
| WO-2024026354-A2 | METHODS AND COMPOSITIONS FOR USE IN TREATING AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) | THE GENERAL HOSPITAL CORPORATION (US) | 2024-02-01 | — | — | WO | claimed |
| CN-110573495-B | Trans-isomeric heterocyclic compounds and process for preparing same | 浙江医药股份有限公司新昌制药厂 | 2023-04-11 | — | — | CN | claimed |
| CN-218459490-U | Feeding device of D, L-naproxen bromination reation kettle | 江苏八巨药业有限公司 | 2023-02-10 | — | — | CN | claimed |
| US-12377072-B2 | Modulators of GTPases and their use | UNM RAINFOREST INNOVATIONS (US) | 2025-08-05 | — | — | US | disclosed |
| CN-120082607-A | Method for splitting chiral acid/alcohol through enzymatic esterification-hydrolysis cascade | 华南理工大学 | 2025-06-03 | — | — | CN | disclosed |
| US-12319952-B2 | Method for enzymatic resolution of chiral substances | SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) | 2025-06-03 | — | — | US | disclosed |
| CN-120058595-A | Chiral amine reagent, preparation method thereof and application thereof in chiral drug resolution and analysis | 安徽医科大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-120009432-A | Method for detecting 9 antipyretic analgesic drugs in feed | 北京市兽药饲料监测中心 | 2025-05-16 | — | — | CN | disclosed |
| CN-116250539-B | Ternary weeding composition containing fenpyrazamine and application thereof | 青岛清原化合物有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119613243-A | Preparation method for converting naproxen impurity into naproxen racemate | 江苏八巨药业有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-11459295-B2 | 2-beta-naphthyl-acetic acid analogs as AKR1C3 inhibitors and methods of using same | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-10-04 | — | — | US | disclosed |
| CN-115043721-A | Preparation method of alpha-substituted chiral carboxylic acid compound | 山东师范大学 | 2022-09-13 | — | — | CN | disclosed |
| EP-3527573-B9 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-110903189-B | Synthesis method of chiral 2-aryl propionate | 大连大学 | 2022-06-21 | — | — | CN | disclosed |
| CN-114394983-A | Synthesis of polycyclic carbamoylpyridone compounds | 吉利德科学公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-112048527-B | Method for splitting chiral substance by double enzyme combination | 华南理工大学 | 2022-04-22 | — | — | CN | disclosed |
| CN-110698499-B | Chiral silver nanocluster and preparation and application thereof | 安徽大学 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459295-B2 | 2-beta-naphthyl-acetic acid analogs as AKR1C3 inhibitors and methods of using same | AKR1C3, AKR1C2, AKR1A1 | PTGS2 294/4885PTGS1 408/4885AKR1C3 1/4885 |
| US-12377072-B2 | Modulators of GTPases and their use | CDC42, RAC1, ROCK1 | PTGS2 2977/4885PTGS1 1972/4885AKR1C3 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.